Table 1 Baseline characteristics of study subjects (n = 2549).
From: A simplified prediction model for end-stage kidney disease in patients with diabetes
Variables | |
Age, years, median (IQR) | 57.0 (47.0–63.0) |
Gender, male, n (%) | 1432 (56.2) |
Smoking, n (%) | |
Smoker | 1133 (44.4) |
Missing | 527 (20.7) |
Body mass index, kg/m2, median (IQR) | 24.2 (21.7–27.4) |
Hypertension, n (%) | 1462 (57.4) |
Dyslipidemia, n (%) | |
Positive | 1836 (72.0) |
Missing | 15 (0.6) |
HbA1c, %, median (IQR) | 7.0 (6.5–8.1) |
mmol/mol, median (IQR) | 53.0 (47.5–65.0) |
Serum albumin, mg/dL, mean (SD) | 4.0 (0.5) |
Serum bilirubin, mg/dL, median (IQR) | 0.7 (0.5–0.9) |
Serum uric acid, mg/dL, mean (SD) | 5.3 (1.5) |
White blood cells, × 103/mL, mean (SD) | 7.21 (2.26) |
Red blood cells, × 106/mL, mean (SD) | 4.44 (0.57) |
Thrombocytes, × 104/mL, mean (SD) | 23.4 (6.9) |
eGFR, mL min−1 [1.73 m]−2, mean (SD) | 81.8 (26.6) |
Proteinuria, n (%) | |
Positive | 475 (29.7) |
Missing, n (%) | 948 (37.2) |
Statin use, n (%) | 865 (33.9) |
Fibrate-related drug use, n (%) | 54 (2.1) |
ARB use, n (%) | 785 (30.8) |
ACE inhibitor use, n (%) | 263 (10.3) |
Erythropoiesis stimulating agent use, n (%) | 42 (1.6) |
GLP-1R agonist use, n (%) | 62 (2.4) |
SGLT2 inhibitor use, n (%) | 51 (2.0) |
Metformin use, n (%) | 517 (20.3) |
Follow-up time, years | |
Median (IQR) | 4.7 (2.3–8.8) |
Mean (SD) | 5.6 (3.7) |
ESKD, n (%) | 176 (6.2) |
Time to ESKD, years | |
Median (IQR) | 2.5 (0.9–4.8) |
Mean (SD) | 3.2 (2.9) |
